Investigational Drug Information for GKT137831
✉ Email this page to a colleague
What is the development status for investigational drug GKT137831?
GKT137831 is an investigational drug.
There have been 5 clinical trials for GKT137831.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 26th 2017.
The most common disease conditions in clinical trials are Idiopathic Interstitial Pneumonias, Albuminuria, and Fibrosis. The leading clinical trial sponsors are Genkyotex SA, Genkyotex Innovation SAS, and Eurofins Optimed.
There are nine US patents protecting this investigational drug and seventy-eight international patents.
Summary for GKT137831
| US Patents | 9 |
| International Patents | 78 |
| US Patent Applications | 43 |
| WIPO Patent Applications | 36 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 2 (2017-06-26) |
| Vendors | 70 |
Recent Clinical Trials for GKT137831
| Title | Sponsor | Phase |
|---|---|---|
| GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis | University of Alabama at Birmingham | Phase 2 |
| Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects | Genkyotex SA | Phase 1 |
| Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets | Eurofins Optimed | Phase 1 |
Clinical Trial Summary for GKT137831
Top disease conditions for GKT137831
Top clinical trial sponsors for GKT137831
US Patents for GKT137831
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GKT137831 | See Plans and Pricing | Selective Nox-1 inhibitor peptides and uses thereof | Universite de Bordeaux (FR) INSERM (FR) | See Plans and Pricing |
| GKT137831 | See Plans and Pricing | Skin enhancing compositions and methods | Sytheon Limited (Boonton, NJ) | See Plans and Pricing |
| GKT137831 | See Plans and Pricing | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (Plan-Les-Ouates, CH) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GKT137831
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GKT137831 | Australia | AU2014204309 | 2033-01-03 | See Plans and Pricing |
| GKT137831 | Brazil | BR112015015242 | 2033-01-03 | See Plans and Pricing |
| GKT137831 | Canada | CA2894576 | 2033-01-03 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
